In patients with "wake-up" stroke selected by noncontrast CT, treatment with tenecteplase did not significantly improve functional outcome at 90 days in the TWIST trial. Although tenecteplase ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Treatment with IV Tenecteplase was not associated with ...

When treating patients with acute ischemic stroke within 4.5 hours of symptom onset, tenecteplase provides noninferior outcomes compared with alteplase (Activase; Genentech), with similar safety, ...

Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...

BARCELONA, Spain — Thrombolysis with tenecteplase led to earlier reperfusion and improved functional outcomes at 90 days without any significant safety issues in selected patients with basilar artery ...